PacBio partners with TychoBio to generate long-read RNA data for AI-designed rare disease therapies

• Pacific Biosciences entered a collaboration with TychoBio to generate full-length RNA sequencing data for AI-driven rare disease RNA therapeutics design.
• TychoBio plans to use PacBio HiFi sequencing with Kinnex long-read RNA sequencing to profile more than 10,000 samples.
• Dataset aims to link steric-blocking antisense oligonucleotide designs to transcriptome-wide effects, with expansion planned to siRNA.
• TychoBio will test candidate therapies across multiple cell types, using sequencing readouts to train models on efficacy, durability, off-target risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060905PRIMZONEFULLFEED9840267) on October 06, 2026, and is solely responsible for the information contained therein.